Pfizer is a global pharmaceutical company and one of the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2025, the company's total revenue stood at about ** billion U.S. dollars. Pfizer’s global positioning Pfizer’s products are available in many countries worldwide, and as of 2024, the company had more than *** research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology, and internal medicine, to name a few. Pfizer’s top products In 2025, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile dysfunction, has also been on the decline, with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

Pfizer's annual revenue was $62.58 B in fiscal year 2025. The annual revenue decreased -$1.05 B from $63.63 B (in 2024) to $62.58 B (in 2025), representing a -1.65% year-over-year decline.

Sales from the United States contributed more than 37 billion U.S. dollars. Pfizer's total revenue was around 63 billion U.S. dollars in 2025. Pfizer sees strong growth in emerging markets Pfizer’s total revenue is divided into four geographic areas: the United States, Developed Markets, and Emerging Markets. China is one of the company’s largest single markets behind the United States, which contributed 60 percent of Pfizer’s total revenue. Pfizer continues to support investment in emerging markets, but the vulnerable nature of these countries means strategies come with an element of risk due to unforeseen financial or political events, for example. The power of product patents Managing the expiration of key patents is one of the greatest challenges facing Pfizer because competition from generic versions can make a big difference to the company's revenues. Many of Pfizer’s leading products enjoy the security of market exclusivity, but less expensive generic versions are free to enter the market when these property rights end. In 2019, Pfizer anticipated a fall in sales revenue from China due to significant competition from generic versions.

In 2024, the revenue from the primary care segment was the highest at about ** billion U.S. dollars. The Primary Care segment, which includes the COVID-19 vaccine Comirnaty, is the company's strongest segment. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. Due to the Upjohn spin-off during 2020 and the Consumer Healthcare business merger with GSK's consumer health segment to form a new joint venture in 2019, only the Biopharma segment remained.

In the third quarter of 2025, Pfizer reported a revenue of **** billion U.S. dollars. This was an increase in comparison to the previous quarter. By failing to prepare, you are preparing to fail The majority of Pfizer’s revenue comes from the manufacture and sale of its products. Pharmaceutical companies are always planning for the future, looking for ways to offset the impact felt when those products start to lose market exclusivity. The development of products is essential for the continued growth of the company, and investing in research and development (R&D) is one way of identifying new, innovative medicines. Pfizer’s R&D expenditure stood at around **** billion U.S. dollars in 2024. Why did Pfizer’s revenues decrease until 2020? Pfizer averaged quarterly revenues of around **** billion U.S. dollars in the four years from the start of 2016 to the end of 2019 – this is considerably lower than the **** billion U.S. dollars the company averaged per quarter in 2010. One reason for the decline was competition from generic drugs that entered the market when key patents expired. Pfizer lost the market exclusivity for its Lipitor product at the end of 2011, and revenues were greatly affected as a consequence. Additionally, following a review of its product portfolio, Pfizer’s revenues were also impacted by the decision to spin off some of its business segments, such as its animal health division in 2013 and its Upjohn business in 2020.

Pfizer reported $17.58B in Sales Revenues for its fiscal quarter ending in December of 2025.Data for Pfizer | PFE - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last March in 2026.

In fiscal year 2025, the revenue per employee at Pfizer was $772.58 K. The revenue per employee increased by $49.55 K from $723.03 K (in 2024) to $772.58 K (in 2025).

Revenues generated from outside the United States accounted for almost ********** of Pfizer's total revenue in 2025. During that year, the company generated revenues of roughly ** billion U.S. dollars in the United States. China emerges as an important market Pfizer sells its pharmaceutical products in more than *** countries worldwide, with the United States, China, and Japan being among the major national markets. In 2024, the United States alone contributed a share of more than ** percent. In terms of geographic area, emerging markets – which include China – generated revenues of approximately *** billion U.S. dollars in 2024. Analyzing Pfizer’s global operations In 2024, Pfizer had approximately 81,000 employees worldwide. The American company had ** manufacturing sites in countries ranging from Belgium to Singapore, each producing products that serviced the company’s commercial division. Pfizer also had several facilities that focused on research and development projects, many of which were located in North America.

In 2025, the company reported basic net earnings per common share of 1.37 U.S. dollars. Pfizer generated a net income of about eight billion U.S. dollars in the same period. The impact of rising costs on earnings per share The net income of Pfizer dramatically increased around fourfold between 2023 and 2024, evident in the company’s net earnings per share, which increased by over one U.S. dollar. Rising research and development costs can be a contributing factor in the decrease in net income. In relation to revenues, the pharmaceutical industry is one of the biggest investors in research and development. Revenues increased due to the COVID-19 vaccine Thanks to record-breaking sales of the COVID-19 vaccine Comirnaty, Pfizer generated its highest total revenues in the years 2021 and 2022. In general, the majority of Pfizer’s revenues comes from the manufacture and sale of its products, and revenues from the company’s domestic market of the United States account for a share of around 60 percent. Pfizer sells its pharmaceutical products in more than 125 countries worldwide, with the United States, China, and Japan being its three largest markets.

View yearly updates and historical trends for Pfizer Inc (PFE) - International Revenue. from United States. Source: Fiscal.ai. Track economic data with YC…

In fiscal year 2025, Pfizer's revenue by segment (products & services) are as follows: Biopharma Segment: $61.20 B.

Pfizer reported $3.54B in Gross Profit on Sales for its fiscal quarter ending in September of 2025.Data for Pfizer | PFE - Gross Profit On Sales including historical, tables and charts were last updated by Trading Economics this last March in 2026.

Comprehensive quarterly and annual earnings data for Pfizer Inc. including revenue, EPS, net income, gross profit, and operating income trajectories. Sourced from SEC EDGAR.

View quarterly updates and historical trends for Pfizer Inc (PFE) - Vyndaqel Family Revenue. from United States. Source: Fiscal.ai. Track economic data wi…

Pfizer generated a net income of over eight billion U.S. dollars in 2024. The company reported basic net earnings per common share of 1.42 U.S. dollars. The impact of rising costs on earnings per share The net income of Pfizer dramatically increased around fourfold between 2023 and 2024, evident in the company’s net earnings per share, which increased by over one U.S. dollar. Rising research and development costs can be a contributing factor in the decrease in the net income. In relation to revenues, the pharmaceutical industry is one of the biggest investors in research and development. Revenues increased due to COVID-19 vaccine Thanks to record-breaking sales of COVID-19 vaccine Comirnaty, Pfizer generated its highest total revenues in the years 2021 and 2022. In general, the majority of Pfizer’s revenues comes from the manufacture and sale of its products, and revenues from the company’s domestic market of the United States accounts for a share of around 60 percent. Pfizer sells its pharmaceutical products in more than 125 countries worldwide, with the United States, China, and Japan being its three largest markets.

United States US: PFE: Revenue (External): Essential Health Product: International: Emerging markets data was reported at 5,775,000.000 USD th in Sep 2018. This records an increase from the previous number of 3,898,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Emerging markets data is updated quarterly, averaging 4,431,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 7,116,000.000 USD th in Dec 2015 and a record low of 1,610,000.000 USD th in Mar 2016. United States US: PFE: Revenue (External): Essential Health Product: International: Emerging markets data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

View yearly updates and historical trends for Pfizer Inc (PFE) - Developed Rest of World Revenue. from United States. Source: Fiscal.ai. Track economic da…

View yearly updates and historical trends for Pfizer Inc (PFE) - Business Innovation (Pfizer CentreOne) Revenue. from United States. Source: Fiscal.ai. Tr…

Pfizer reported $4.65B in EBIT for its fiscal quarter ending in December of 2025.Data for Pfizer | PFE - Ebit including historical, tables and charts were last updated by Trading Economics this last March in 2026.

This statistic depicts revenues of pharmaceutical company Pfizer from 2017 to 2019, by segment. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2019, Pfizer's Biopharma (IH) segment generated some 39.4 billion U.S. dollars of revenue. Pfizer is the world's largest company based on pure pharmaceutical revenue. Due to the Upjohn spin-off during 2020 and the Consumer Healthcare business merger with GSK's consumer health segment to a joint venturre in 2019, only the Biopharma segment remained.